These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 873714)

  • 1. A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients.
    Chouinard G; Annable L; Serrano M; Charette R
    Int Pharmacopsychiatry; 1977; 12(1):1-8. PubMed ID: 873714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.
    Young SN; Gauthier S; Chouinard G; Anderson GM; Purdy WC
    J Neural Transm; 1982; 53(1):83-7. PubMed ID: 6801200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled study of tryptophan-benserazide in schizophrenia.
    Chouinard Q; Annable L; Young SN; Sourkes TL
    Commun Psychopharmacol; 1978; 2(1):21-31. PubMed ID: 350483
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.
    Gerlach J; Lühdorf K
    Psychopharmacologia; 1975 Oct; 44(1):105-10. PubMed ID: 706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
    Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
    Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
    Rinne UK; Birket-Smith E; Dupont E; Hansen E; Hyyppä M; Marttila R; Mikkelsen B; Pakkenberg H; Presthus J
    J Neurol; 1975 Dec; 211(1):1-9. PubMed ID: 56427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
    Bender DA; Earl CJ; Lees AJ
    Clin Sci (Lond); 1979 Jan; 56(1):89-93. PubMed ID: 477187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 13. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
    Sachs C; Berglund B; Kaijser L
    Acta Neurol Scand; 1985 Jan; 71(1):37-42. PubMed ID: 3976351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 15. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 17. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H; Siegfried J
    Eur Neurol; 1976; 14(5):321-8. PubMed ID: 949985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of L-dopa on polycythemia.
    Herishanu Y; Rosenberg P
    J Am Geriatr Soc; 1977 May; 25(5):218-9. PubMed ID: 853205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.